Abivax’s lead candidate, ABX464, is gearing up to launch a Phase III program this year in about 1,400 patients with moderate-to-severe ulcerative colitis (UC). The company has held an end-of-Phase II meeting with the FDA and received scientific feedback from the European Medicines Agency. Both agencies supported ABX464 advancing into Phase III. Abivax’s treatments are designed to modulate the body’s inflammation and immunological pathways . . .
Home Gastrointestinal Disorders Inflection Point: Abivax Challenges Pharma Giants in Ulcerative Colitis

- Bristol-Myers Squibb
- Cancer
- Drug Discovery
- Eli Lilly
- Gastrointestinal Disorders
- GEN Edge
- Inflammatory Diseases
- Pfizer
- Small Molecules
Inflection Point: Abivax Challenges Pharma Giants in Ulcerative Colitis
French biopharma gears up for Phase III trial of lead candidate ABX464 as BMS, Pfizer and Lilly pursue UC treatments
Inflammatory pseudopolyps from a total colectomy done for clinically severe, intractable chronic ulcerative colitis (UC). Abivax’s lead candidate, ABX464, is gearing up to launch a Phase III program toward the end of the second quarter in about 1,400 patients with moderate-to-severe UC. [Ed Uthman, MD via Wikidata]